We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Different outcomes in sporadic versus familial medullary thyroid cancer.
- Authors
Saltiki, Katerina; Simeakis, George; Anagnostou, Elli; Zapanti, Evangelia; Anastasiou, Eleni; Alevizaki, Maria
- Abstract
Background: Medullary thyroid carcinoma (MTC) has varying clinical course with familial cases (fMTC) diagnosed earlier than sporadic MTC (spMTC). Methods: A total of 273 MTCs (familial: n = 110 [40.3%], males: 38.5%) were followed for 1‐35 years (median 5.0 years). Fifty one of the familial cases were operated because of positive findings at genetic screening. Disease extent at diagnosis and follow‐up was recorded. Results: Mean age at diagnosis was: fMTC = 33.85 ± 16.5 years (range 4‐74) and spMTC = 52.6 ± 14.0 years (range 16‐81, P < .001). This difference remained when genetic screening cases were excluded. fMTCs had more frequently multifocality, smaller size, and more favorable stage at diagnosis (stages I and II: 60.9% vs 47.9%, stage III: 30.0% vs 23.9%, stage IV: 9.1% vs 28.9%, P = .01). fMTC had lower preoperative and postoperative calcitonin, more frequently remission (59.1% vs 47.2%) and less frequently progressive disease (8.2% vs 35.0%, P < .001). After excluding genetic screening cases, no difference in stage at diagnosis was observed. Outcome was more favorable in fMTC compared to sporadic (P = .002); the 10‐year probability of lack of progression of disease differed significantly between fMTCs and spMTCs (86.4% vs 65.0%, P < .001). Conclusion: After excluding genetic screening cases, although stage at diagnosis is similar, disease outcome remains worse in sporadic compared to fMTCs.
- Subjects
MEDULLARY thyroid carcinoma; GENETIC testing; CALCITONIN; CANCER remission; CANCER invasiveness
- Publication
Head & Neck, 2019, Vol 41, Issue 1, p154
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.25463